Saudi Pharmaceutical Industries and Medical Appliances Corporation (Spimaco), Saudi Arabia's largest pharmaceutical products producer, reported a net profit of SAR 337 million for H1-2015, a 78.4 percent increase compared to the same period last year.
Spimaco attributed the increase to higher sales and realizing a capital gain of SAR 151.3 million from the sale of its stake in Eirgen Pharma Ltd.
Item | 6m 2014 | 6m 2015 | Change |
---|---|---|---|
Revenues | 776.35 | 868.00 | 11.8 % |
Gross Income | 399.87 | 436.81 | 9.2 % |
Operating Income | 120.95 | 139.36 | 15.2 % |
Net Income | 188.88 | 337.02 | 78.4 % |
Average Shares | 120.00 | 120.00 | - |
EPS (Riyals) | 1.57 | 2.81 | 78.4 % |
The company reported a net profit of SAR 237.6 million in Q2 this year, compared to a net profit of SAR 97.7 million in the same quarter last year.
Item | Q2 2014 | Q2 2015 | Change |
---|---|---|---|
Revenues | 371.14 | 435.80 | 17.4 % |
Gross Income | 193.14 | 210.95 | 9.2 % |
Operating Income | 44.90 | 48.02 | 6.9 % |
Net Income | 97.72 | 237.63 | 143.2 % |
Average Shares | 120.00 | 120.00 | - |
EPS (Riyals) | 0.81 | 1.98 | 143.2 % |
Item | Q1 2015 | Q2 2015 | Change |
---|---|---|---|
Revenues | 432.20 | 435.80 | 0.8 % |
Gross Income | 225.86 | 210.95 | (6.6 %) |
Operating Income | 91.35 | 48.02 | (47.4 %) |
Net Income | 99.39 | 237.63 | 139.1 % |
Average Shares | 120.00 | 120.00 | - |
EPS (Riyals) | 0.83 | 1.98 | 139.1 % |
Period | Revenues | Change | Gross Income | Change | Net Income | Change | EPS(Riyal) |
---|---|---|---|---|---|---|---|
Q1 2006 | 194.37 | 17.1 % | 91.95 | 23.6 % | 37.65 | 6.4 % | 0.37 |
Q2 2006 | 185.74 | 21.6 % | 71.43 | 19.9 % | 19.13 | (21.2 %) | 0.19 |
Q3 2006 | 156.57 | 10.9 % | 64.50 | 9.4 % | 23.80 | 15.1 % | 0.23 |
Q4 2006 | 191.16 | 1.1 % | 80.54 | 3.1 % | 24.46 | 54.8 % | 0.24 |
2006 | 727.84 | 12.2 % | 308.42 | 13.8 % | 105.04 | 9.2 % | 1.03 |
Q1 2007 | 203.37 | 4.6 % | 91.01 | (1.0 %) | 39.50 | 4.9 % | 0.39 |
Q2 2007 | 209.28 | 12.7 % | 66.46 | (7.0 %) | 22.57 | 18.0 % | 0.22 |
Q3 2007 | 149.40 | (4.6 %) | 66.84 | 3.6 % | 26.53 | 11.4 % | 0.26 |
Q4 2007 | 235.70 | 23.3 % | 102.31 | 27.0 % | 33.28 | 36.1 % | 0.33 |
2007 | 797.75 | 9.6 % | 326.62 | 5.9 % | 121.87 | 16.0 % | 1.20 |
Q1 2008 | 220.58 | 8.5 % | 99.57 | 9.4 % | 40.93 | 3.6 % | 0.40 |
Q2 2008 | 211.66 | 1.1 % | 74.78 | 12.5 % | 34.24 | 51.7 % | 0.34 |
Q3 2008 | 145.45 | (2.6 %) | 74.34 | 11.2 % | 15.62 | (41.1 %) | 0.15 |
Q4 2008 | 294.26 | 24.8 % | 114.28 | 11.7 % | 37.48 | 12.6 % | 0.37 |
2008 | 871.94 | 9.3 % | 362.97 | 11.1 % | 128.27 | 5.2 % | 1.26 |
Q1 2009 | 257.88 | 16.9 % | 108.57 | 9.0 % | 42.69 | 4.3 % | 0.42 |
Q2 2009 | 229.00 | 8.2 % | 81.53 | 9.0 % | 37.81 | 10.4 % | 0.37 |
Q3 2009 | 171.15 | 17.7 % | 72.49 | (2.5 %) | 15.84 | 1.4 % | 0.16 |
Q4 2009 | 292.71 | (0.5 %) | 157.00 | 37.4 % | 58.48 | 56.0 % | 0.58 |
2009 | 950.74 | 9.0 % | 419.59 | 15.6 % | 154.81 | 20.7 % | 1.53 |
Q1 2010 | 274.33 | 6.4 % | 118.90 | 9.5 % | 45.32 | 6.2 % | 0.38 |
Q2 2010 | 252.34 | 10.2 % | 100.50 | 23.3 % | 43.09 | 14.0 % | 0.36 |
Q3 2010 | 191.40 | 11.8 % | 85.88 | 18.5 % | 18.07 | 14.1 % | 0.15 |
Q4 2010 | 319.57 | 9.2 % | 181.12 | 15.4 % | 70.04 | 19.8 % | 0.58 |
2010 | 1,037.64 | 9.1 % | 486.40 | 15.9 % | 176.52 | 14.0 % | 1.47 |
Q1 2011 | 252.08 | (8.1 %) | 123.51 | 3.9 % | 45.71 | 0.9 % | 0.38 |
Q2 2011 | 292.08 | 15.7 % | 123.61 | 23.0 % | 60.75 | 41.0 % | 0.51 |
Q3 2011 | 209.24 | 9.3 % | 106.76 | 24.3 % | 29.75 | 64.6 % | 0.25 |
Q4 2011 | 375.82 | 17.6 % | 206.69 | 14.1 % | 74.06 | 5.7 % | 0.62 |
2011 | 1,129.22 | 8.8 % | 560.57 | 15.2 % | 211.44 | 19.8 % | 1.76 |
Q1 2012 | 303.14 | 20.3 % | 153.21 | 24.0 % | 56.45 | 23.5 % | 0.47 |
Q2 2012 | 286.64 | (1.9 %) | 140.91 | 14.0 % | 90.14 | 48.4 % | 0.75 |
Q3 2012 | 227.40 | 8.7 % | 113.28 | 6.1 % | 32.33 | 8.7 % | 0.27 |
Q4 2012 | 365.97 | (2.6 %) | 211.16 | 2.2 % | 53.73 | (27.5 %) | 0.45 |
2012 | 1,183.15 | 4.8 % | 618.56 | 10.3 % | 232.65 | 10.0 % | 1.94 |
Q1 2013 | 361.37 | 19.2 % | 184.62 | 20.5 % | 63.15 | 11.9 % | 0.53 |
Q2 2013 | 344.22 | 20.1 % | 179.12 | 27.1 % | 113.71 | 26.1 % | 0.95 |
Q3 2013 | 222.91 | (2.0 %) | 118.64 | 4.7 % | 34.19 | 5.8 % | 0.28 |
Q4 2013 | 382.01 | 4.4 % | 226.14 | 7.1 % | 57.01 | 6.1 % | 0.48 |
2013 | 1,310.50 | 10.8 % | 708.52 | 14.5 % | 266.82 | 14.7 % | 2.22 |
Q1 2014 | 405.21 | 12.1 % | 206.72 | 12.0 % | 91.17 | 44.4 % | 0.76 |
Q2 2014 | 371.14 | 7.8 % | 193.14 | 7.8 % | 97.72 | (14.1 %) | 0.81 |
Q3 2014 | 266.02 | 19.3 % | 134.45 | 13.3 % | 36.69 | 7.3 % | 0.31 |
Q4 2014 | 431.06 | 12.8 % | 261.80 | 15.8 % | 91.29 | 60.1 % | 0.76 |
2014 | 1,470.19 | 12.2 % | 794.54 | 12.1 % | 316.85 | 18.8 % | 2.64 |
Q1 2015 | 432.20 | 6.7 % | 225.86 | 9.3 % | 99.39 | 9.0 % | 0.83 |
Q2 2015 | 435.80 | 17.4 % | 210.95 | 9.2 % | 237.63 | 143.2 % | 1.98 |
Period | Revenues | Change | Gross Income | Change | Net Income | Change | EPS(Riyal) |
---|---|---|---|---|---|---|---|
2005 | 648.90 | 11.4 % | 271.07 | 26.3 % | 96.15 | 46.8 % | 0.95 |
2006 | 727.84 | 12.2 % | 308.42 | 13.8 % | 105.04 | 9.2 % | 1.03 |
2007 | 797.75 | 9.6 % | 326.62 | 5.9 % | 121.87 | 16.0 % | 1.20 |
2008 | 871.94 | 9.3 % | 362.97 | 11.1 % | 128.27 | 5.2 % | 1.26 |
2009 | 950.74 | 9.0 % | 419.59 | 15.6 % | 154.81 | 20.7 % | 1.53 |
2010 | 1,037.64 | 9.1 % | 486.40 | 15.9 % | 176.52 | 14.0 % | 1.47 |
2011 | 1,129.22 | 8.8 % | 560.57 | 15.2 % | 211.44 | 19.8 % | 1.76 |
2012 | 1,183.15 | 4.8 % | 618.56 | 10.3 % | 232.65 | 10.0 % | 1.94 |
2013 | 1,310.50 | 10.8 % | 708.52 | 14.5 % | 266.82 | 14.7 % | 2.22 |
2014 | 1,470.19 | 12.2 % | 794.54 | 12.1 % | 316.85 | 18.8 % | 2.64 |
Period | Gross Margin | OIBDA Margin | Net Margin Before Unusual Items |
---|---|---|---|
Q1 2006 | 42.61 % | 18.61 % | 14.53 % |
Q2 2006 | 42.30 % | 18.33 % | 13.13 % |
Q3 2006 | 42.16 % | 18.23 % | 13.28 % |
Q4 2006 | 42.37 % | 17.65 % | 14.43 % |
2006 | 42.37 % | 17.65 % | 14.43 % |
Q1 2007 | 41.73 % | 17.98 % | 14.51 % |
Q2 2007 | 39.78 % | 14.82 % | 14.51 % |
Q3 2007 | 40.47 % | 15.48 % | 15.01 % |
Q4 2007 | 40.94 % | 15.79 % | 15.28 % |
2007 | 40.94 % | 15.79 % | 15.28 % |
Q1 2008 | 41.13 % | 15.70 % | 15.13 % |
Q2 2008 | 42.03 % | 16.67 % | 16.57 % |
Q3 2008 | 43.15 % | 16.47 % | 15.83 % |
Q4 2008 | 41.63 % | 16.30 % | 15.25 % |
2008 | 41.63 % | 16.30 % | 15.16 % |
Q1 2009 | 40.91 % | 16.13 % | 14.83 % |
Q2 2009 | 40.87 % | 16.44 % | 14.89 % |
Q3 2009 | 39.57 % | 15.73 % | 14.07 % |
Q4 2009 | 44.13 % | 18.49 % | 16.63 % |
2009 | 44.13 % | 18.49 % | 16.63 % |
Q1 2010 | 44.45 % | 18.88 % | 16.94 % |
Q2 2010 | 45.32 % | 18.93 % | 17.07 % |
Q3 2010 | 45.73 % | 18.73 % | 16.95 % |
Q4 2010 | 46.88 % | 18.85 % | 17.32 % |
2010 | 46.88 % | 18.85 % | 17.32 % |
Q1 2011 | 48.36 % | 18.99 % | 17.42 % |
Q2 2011 | 48.73 % | 19.12 % | 18.44 % |
Q3 2011 | 49.86 % | 19.99 % | 19.22 % |
Q4 2011 | 49.64 % | 19.57 % | 18.62 % |
2011 | 49.64 % | 19.65 % | 18.72 % |
Q1 2012 | 50.01 % | 19.86 % | 18.73 % |
Q2 2012 | 51.72 % | 20.36 % | 21.31 % |
Q3 2012 | 51.47 % | 20.54 % | 21.21 % |
Q4 2012 | 52.28 % | 19.56 % | 19.66 % |
2012 | 52.28 % | 19.56 % | 19.66 % |
Q1 2013 | 52.36 % | 19.26 % | 19.28 % |
Q2 2013 | 52.98 % | 18.87 % | 20.24 % |
Q3 2013 | 53.58 % | 18.66 % | 20.45 % |
Q4 2013 | 54.06 % | 18.26 % | 20.45 % |
2013 | 54.06 % | 18.16 % | 20.36 % |
Q1 2014 | 53.95 % | 17.92 % | 21.86 % |
Q2 2014 | 53.91 % | 17.74 % | 20.28 % |
Q3 2014 | 53.39 % | 16.79 % | 19.84 % |
Q4 2014 | 54.03 % | 18.15 % | 21.50 % |
2014 | 54.04 % | 18.15 % | 21.55 % |
Q1 2015 | 54.34 % | 18.90 % | 21.67 % |
Q2 2015 | 53.23 % | 18.31 % | 20.04 % |
Period | Gross Margin | OIBDA Margin | Net Margin Before Unusual Items |
---|---|---|---|
2005 | 41.77 % | 18.97 % | 14.82 % |
2006 | 42.37 % | 17.65 % | 14.43 % |
2007 | 40.94 % | 15.79 % | 15.28 % |
2008 | 41.63 % | 16.30 % | 15.16 % |
2009 | 44.13 % | 18.49 % | 16.63 % |
2010 | 46.88 % | 18.85 % | 17.32 % |
2011 | 49.64 % | 19.65 % | 18.72 % |
2012 | 52.28 % | 19.56 % | 19.66 % |
2013 | 54.06 % | 18.16 % | 20.36 % |
2014 | 54.04 % | 18.15 % | 21.55 % |
Period | Gross Margin | OIBDA Margin | Net Margin Before Unusual Items |
---|---|---|---|
Q1 2006 | 47.31 % | 22.09 % | 19.37 % |
Q2 2006 | 38.46 % | 16.07 % | 10.30 % |
Q3 2006 | 41.20 % | 17.41 % | 15.20 % |
Q4 2006 | 42.13 % | 14.88 % | 12.80 % |
Q1 2007 | 44.75 % | 23.06 % | 19.42 % |
Q2 2007 | 31.76 % | 4.83 % | 10.79 % |
Q3 2007 | 44.74 % | 20.85 % | 17.75 % |
Q4 2007 | 43.41 % | 16.03 % | 14.12 % |
Q1 2008 | 45.14 % | 22.16 % | 18.55 % |
Q2 2008 | 35.33 % | 8.71 % | 16.39 % |
Q3 2008 | 51.11 % | 19.82 % | 13.64 % |
Q4 2008 | 38.84 % | 15.63 % | 12.74 % |
Q1 2009 | 42.10 % | 20.70 % | 16.62 % |
Q2 2009 | 35.60 % | 10.54 % | 16.51 % |
Q3 2009 | 42.35 % | 15.37 % | 9.25 % |
Q4 2009 | 53.64 % | 24.60 % | 21.04 % |
Q1 2010 | 43.34 % | 21.92 % | 17.70 % |
Q2 2010 | 39.83 % | 11.52 % | 17.08 % |
Q3 2010 | 44.87 % | 14.68 % | 9.44 % |
Q4 2010 | 56.68 % | 24.50 % | 21.92 % |
Q1 2011 | 49.00 % | 22.74 % | 18.13 % |
Q2 2011 | 42.32 % | 13.00 % | 20.80 % |
Q3 2011 | 51.02 % | 19.57 % | 14.22 % |
Q4 2011 | 55.00 % | 22.56 % | 19.71 % |
Q1 2012 | 50.54 % | 23.32 % | 18.62 % |
Q2 2012 | 49.16 % | 14.95 % | 31.45 % |
Q3 2012 | 49.82 % | 20.53 % | 14.22 % |
Q4 2012 | 57.70 % | 19.47 % | 14.68 % |
Q1 2013 | 51.09 % | 21.68 % | 17.48 % |
Q2 2013 | 52.04 % | 14.20 % | 33.03 % |
Q3 2013 | 53.22 % | 19.34 % | 15.34 % |
Q4 2013 | 59.20 % | 18.05 % | 14.92 % |
Q1 2014 | 51.02 % | 20.19 % | 22.50 % |
Q2 2014 | 52.04 % | 13.80 % | 26.33 % |
Q3 2014 | 50.54 % | 13.97 % | 13.79 % |
Q4 2014 | 60.73 % | 22.54 % | 21.18 % |
Q1 2015 | 52.26 % | 22.70 % | 23.00 % |
Q2 2015 | 48.40 % | 12.42 % | 19.81 % |
Period | Shares Outstanding (M) | EPS (Riyal) | Adjusted EPS (Riyal) | Book Value (BV) |
---|---|---|---|---|
Q1 2006 | 101.51 | 0.97 | 0.97 | 25.43 |
Q2 2006 | 101.51 | 0.92 | 0.92 | 21.37 |
Q3 2006 | 101.51 | 0.95 | 0.95 | 27.26 |
Q4 2006 | 101.51 | 1.03 | 1.03 | 19.65 |
Q1 2007 | 101.51 | 1.05 | 1.05 | 19.84 |
Q2 2007 | 101.51 | 1.09 | 1.09 | 19.42 |
Q3 2007 | 101.51 | 1.11 | 1.11 | 21.04 |
Q4 2007 | 101.51 | 1.20 | 1.20 | 28.41 |
Q1 2008 | 101.51 | 1.21 | 1.21 | 26.83 |
Q2 2008 | 101.51 | 1.33 | 1.33 | 27.74 |
Q3 2008 | 101.51 | 1.22 | 1.27 | 21.88 |
Q4 2008 | 101.51 | 1.26 | 1.31 | 13.76 |
Q1 2009 | 101.51 | 1.28 | 1.33 | 14.17 |
Q2 2009 | 101.51 | 1.32 | 1.36 | 17.62 |
Q3 2009 | 101.51 | 1.32 | 1.32 | 19.72 |
Q4 2009 | 101.51 | 1.53 | 1.56 | 21.46 |
Q1 2010 | 120.00 | 1.31 | 1.36 | 22.04 |
Q2 2010 | 120.00 | 1.36 | 1.41 | 19.98 |
Q3 2010 | 120.00 | 1.37 | 1.43 | 21.69 |
Q4 2010 | 120.00 | 1.47 | 1.50 | 24.48 |
Q1 2011 | 120.00 | 1.47 | 1.47 | 25.41 |
Q2 2011 | 120.00 | 1.62 | 1.62 | 27.29 |
Q3 2011 | 120.00 | 1.72 | 1.72 | 25.92 |
Q4 2011 | 120.00 | 1.75 | 1.75 | 26.50 |
Q1 2012 | 120.00 | 1.84 | 1.84 | 30.26 |
Q2 2012 | 120.00 | 2.09 | 2.09 | 25.75 |
Q3 2012 | 120.00 | 2.11 | 2.11 | 26.24 |
Q4 2012 | 120.00 | 1.94 | 1.94 | 25.28 |
Q1 2013 | 120.00 | 1.99 | 1.99 | 27.18 |
Q2 2013 | 120.00 | 2.19 | 2.19 | 26.14 |
Q3 2013 | 120.00 | 2.21 | 2.21 | 27.35 |
Q4 2013 | 120.00 | 2.23 | 2.23 | 32.18 |
Q1 2014 | 120.00 | 2.47 | 2.47 | 32.96 |
Q2 2014 | 120.00 | 2.33 | 2.33 | 33.21 |
Q3 2014 | 120.00 | 2.35 | 2.35 | 35.74 |
Q4 2014 | 120.00 | 2.64 | 2.64 | 28.75 |
Q1 2015 | 120.00 | 2.71 | 2.71 | 27.84 |
Q2 2015 | 120.00 | 3.87 | 2.61 | 28.72 |
Period | Shares Outstanding (M) | EPS (Riyal) | Adjusted EPS (Riyal) | Book Value (BV) |
---|---|---|---|---|
2005 | 101.51 | 0.95 | 0.95 | 20.18 |
2006 | 101.51 | 1.03 | 1.03 | 19.65 |
2007 | 101.51 | 1.20 | 1.20 | 28.41 |
2008 | 101.51 | 1.26 | 1.30 | 13.76 |
2009 | 101.51 | 1.53 | 1.56 | 21.46 |
2010 | 120.00 | 1.47 | 1.50 | 24.48 |
2011 | 120.00 | 1.76 | 1.76 | 26.50 |
2012 | 120.00 | 1.94 | 1.94 | 25.28 |
2013 | 120.00 | 2.22 | 2.22 | 32.18 |
2014 | 120.00 | 2.64 | 2.64 | 28.75 |
Period | P/E | Adjusted P/E | Price/book |
---|---|---|---|
Q1 2006 | More than 100 | More than 100 | 4.07 |
Q2 2006 | 97.11 | 97.11 | 4.18 |
Q3 2006 | 89.06 | 89.06 | 3.10 |
Q4 2006 | 33.13 | 33.13 | 1.74 |
Q1 2007 | 30.19 | 30.19 | 1.60 |
Q2 2007 | 28.33 | 28.33 | 1.59 |
Q3 2007 | 28.70 | 28.70 | 1.52 |
Q4 2007 | 33.83 | 33.83 | 1.43 |
Q1 2008 | 27.68 | 27.68 | 1.25 |
Q2 2008 | 26.79 | 26.70 | 1.28 |
Q3 2008 | 20.49 | 19.74 | 1.14 |
Q4 2008 | 12.99 | 12.53 | 1.19 |
Q1 2009 | 14.92 | 14.39 | 1.35 |
Q2 2009 | 17.20 | 16.65 | 1.28 |
Q3 2009 | 18.29 | 18.26 | 1.22 |
Q4 2009 | 15.25 | 14.94 | 1.08 |
Q1 2010 | 16.69 | 16.04 | 0.99 |
Q2 2010 | 14.70 | 14.15 | 1.00 |
Q3 2010 | 14.64 | 14.10 | 0.93 |
Q4 2010 | 15.82 | 15.53 | 0.95 |
Q1 2011 | 17.65 | 17.65 | 1.02 |
Q2 2011 | 15.68 | 15.68 | 0.93 |
Q3 2011 | 14.41 | 14.41 | 0.96 |
Q4 2011 | 15.03 | 15.03 | 0.99 |
Q1 2012 | 17.92 | 17.92 | 1.09 |
Q2 2012 | 12.56 | 12.56 | 1.02 |
Q3 2012 | 13.70 | 13.70 | 1.10 |
Q4 2012 | 14.74 | 14.74 | 1.13 |
Q1 2013 | 13.60 | 13.60 | 1.00 |
Q2 2013 | 15.51 | 15.51 | 1.30 |
Q3 2013 | 15.70 | 15.70 | 1.27 |
Q4 2013 | 19.02 | 19.02 | 1.32 |
Q1 2014 | 19.07 | 19.07 | 1.43 |
Q2 2014 | 19.29 | 19.29 | 1.36 |
Q3 2014 | 21.41 | 21.41 | 1.41 |
Q4 2014 | 12.89 | 12.89 | 1.18 |
Q1 2015 | 14.78 | 14.78 | 1.44 |
Q2 2015 | 11.59 | 17.18 | 1.56 |
Period | P/E | Adjusted P/E | Price/book |
---|---|---|---|
2005 | More than 100 | More than 100 | 6.89 |
2006 | 33.13 | 33.13 | 1.74 |
2007 | 33.83 | 33.83 | 1.43 |
2008 | 12.99 | 12.60 | 1.19 |
2009 | 15.25 | 14.94 | 1.08 |
2010 | 15.82 | 15.53 | 0.95 |
2011 | 14.95 | 14.95 | 0.99 |
2012 | 14.74 | 14.74 | 1.13 |
2013 | 19.11 | 19.11 | 1.32 |
2014 | 12.89 | 12.89 | 1.18 |
Q2 2015
2015
Period | Medical & Pharmaceutical production segment | Investment activity |
---|---|---|
Q1 2006 | 194.37 | - |
Q2 2006 | 185.74 | - |
Q3 2006 | 156.57 | - |
Q4 2006 | 191.16 | - |
Q1 2007 | 203.37 | - |
Q2 2007 | 209.28 | - |
Q3 2007 | 149.40 | - |
Q4 2007 | 235.69 | - |
Q1 2008 | 220.58 | - |
Q2 2008 | 211.66 | - |
Q3 2008 | 145.45 | - |
Q4 2008 | 294.25 | - |
Q1 2009 | 257.88 | - |
Q2 2009 | 229.00 | - |
Q3 2009 | 171.15 | - |
Q4 2009 | 292.71 | - |
Q1 2010 | 274.33 | - |
Q2 2010 | 252.34 | - |
Q3 2010 | 191.41 | - |
Q4 2010 | 319.57 | - |
Q1 2011 | 252.08 | - |
Q2 2011 | 292.08 | - |
Q3 2011 | 209.24 | - |
Q4 2011 | 375.82 | - |
Q1 2012 | 303.14 | - |
Q2 2012 | 286.65 | - |
Q3 2012 | 227.40 | - |
Q4 2012 | 365.97 | - |
Q1 2013 | 361.37 | - |
Q2 2013 | 344.22 | - |
Q3 2013 | 222.91 | - |
Q4 2013 | 382.01 | - |
Q1 2014 | 405.21 | - |
Q2 2014 | 374.14 | - |
Q3 2014 | 266.02 | - |
Q4 2014 | 427.82 | - |
Q1 2015 | 432.29 | 14.84 |
Q2 2015 | 436.99 | 195.93 |
Period | Medical & Pharmaceutical production segment | Investment activity |
---|---|---|
2005 | 648.90 | - |
2006 | 727.84 | - |
2007 | 797.75 | - |
2008 | 871.94 | - |
2009 | 950.74 | - |
2010 | 1,037.64 | - |
2011 | 1,129.22 | - |
2012 | 1,183.15 | - |
2013 | 1,310.50 | - |
2014 | 1,470.19 | - |
Current | |
Market Cap (M Riyal) | 3,444.00 |
Enterprise Value (EV) (M) | 4,525.48 |
Shares Outstanding ((M)) | 120.00 |
EPS ( Riyal) (TTM) | (0.27) |
Book Value (BV) ( Riyal) | 12.89 |
Par Value ( Riyal) | 10.00 |
Adjusted P/E (Last12) | Neg |
P/E (TTM) | NEG |
Price/book | 2.23 |
Return on Average Assets (%) (TTM) | (0.76 ) |
Return on Average Equity (%) (TTM) | (2.09 ) |
Argaam Investment Company has updated the Privacy Policy of its services and digital platforms. Know more about our Privacy Policy here.
Argaam uses cookies to personalize content, to provide social media features and analyze traffic, that we might also share with third parties. You consent to our cookies if you use this website
Comments {{getCommentCount()}}
Be the first to comment
رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}
{{comment.DisplayName}}
{{comment.ElapsedTime}}